Life Science Intelligence

  In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, announce regulatory clearances, and much more on the road to  LSI USA  ’26 in Dana Point (March 17–21). AccurKardia Announced the launch of a multicenter clinical pilot for AK+ Guard™, its FDA Breakthrough Device Designated AI-powered technology for detecting hyperkalemia using Lead I ECG. The study will evaluate over 150 patients across care settings and aims to validate the platform’s ability to deliver real-time, remote monitoring through consumer and clinical wearables. Amber Implants Received FDA 510(k) clearance for its VCFixⓇ Spinal System, a minimally invasive vertebral augmentation device designed to treat vertebral compression fractures. One-year follow-up data from initial clinical trials showed sustained pain reduction and faster recovery, supporting Amber’s plan to begin its U.S. commercial launch with a pilot program in early 2026. A...

Military health is about preparedness by making sure our servicemen and women are ready for what is in front of them, these emerging technologies from these non-dilutive investments by the US government have continuously been beneficial. DOD, DARPA, NIH, and NASA have been behind some of the largest healthcare / medtech platforms. For more information watch this video  https://www.youtube.com/watch?v=T66RWqDM7NY&t=1s  

  Ambulatory surgical centers, home-health, telehealth centers, retail health facilities are quickly expanding from the legacy hospital model. Nadine Hachach-Haram and David Uffer discuss their thoughts on where the pressure points and areas of interest might be in the changing centers of care. For more information watch this video:  https://www.youtube.com/watch?v=UyspPOXeiMs&t=38s

Organ transplantation has transformed modern medicine, yet one of the greatest hurdles remains the preservation of donor organs between recovery and implantation. Organ preservation refers to the methods and technologies used to keep hearts, livers, kidneys, lungs, and other organs viable until they can be transplanted into recipients. The effectiveness of preservation directly influences patient outcomes, organ utilization rates, and the economics of transplant programs. For decades, static cold storage (SCS) has been the gold standard. Organs are cooled on ice to slow metabolism, a simple and inexpensive solution that works reasonably well at scale. But it has major shortcomings: cold storage cannot prevent ischemic injury, it provides no way to test organ function before transplant, and it contributes to the high rate of discarded organs. This is where OrganOx has made its mark. The company’s metra system, an NMP platform for livers, allows surgeons to keep donor livers “alive” outs...

  The environment for medtech IPOs has shifted noticeably in 2025. After a sluggish 2024, where only a handful of device makers found their way to public markets, the tide is beginning to turn. Eight months into the year, six companies in the U.S. device space have gone public. That’s a meaningful jump compared to last year and could mark the beginning of a more sustained reopening of the IPO pathway. Before looking at the individual debuts, it’s worth stepping back to understand why the landscape for medtech IPOs feels different this year. Why IPOs Matter for Medtech For  medtech companies  at the right point on their growth curve, going public can be transformative. Beyond raising capital, an IPO can provide: Funding at scale for launches, pivotal trials, and global expansion Transparency and visibility through SEC filings and broader analyst coverage Liquidity and optionality for future strategic moves, including acquisitions Of course, accessing the public markets bri...

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, announce regulatory milestones, and much more on the road to  LSI USA  ’26 in Dana Point (March 17–21). CustomSurg Announced that OrthoPlanner™, a surgeon-designed digital tool that streamlines pre-operative fracture planning, received FDA clearance for all fracture anatomies. Accessible on smartphones and PCs, the platform enables faster, more precise trauma surgery with no additional hardware or setup required. Gleamer Received the Special Jury Prize at the EY Entrepreneur of the Year awards in recognition of its mission to bring trustworthy AI into radiology. Gleamer’s medical-grade AI solutions are designed to support diagnostic accuracy and workflow efficiency to improve care for millions of patients worldwide. Madison Scientific Raised $10M in an oversubscribed seed round to accelerate development of the SmartShunt™ Hydrocephalus Management System....

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funds, receive regulatory approvals, and much more on the road to  LSI Europe  ’25 in London (September 7–11). AVASA Completed the first close of an oversubscribed Pre-Series A round led by Movac, raising NZD$4.75M to advance its category-defining AVASA Coupler device. The funding enables Avasa to complete FDA clearance and prepare for the commercial launch of its microsurgical solution for standardized arterial reconnection. Ciliatech Received CE mark approval for Intercil, a uveal spacer eye implant that treats glaucoma via a novel cilioscleral interpositioning approach. The implant aims to preserve anterior chamber integrity using a “no-bleb-no-cleft” method and is now set for commercial rollout across Europe with future expansion into the U.S. and China. Facet Dynamics Secured private equity funding to support regulatory efforts, including a pivotal, multi-ce...